BiondVax rounds up $9.5M in IPO

BiondVax ($BVXV) raised $9.5 million in a Nasdaq IPO, pricing 1,910,000 shares at $5.01 each. The Israel-based company is working on a universal flu vaccine to protect against all strains of the virus, including seasonal strains and pandemics. CEO Ron Babecoff said the funds will allow BiondVax to "promote its clinical activities and speed it up while developing business-wise," Globes reported. More

Read more on